Akèy › Karsinòm selil skuamèz tèt ak kou › Massachusetts
Etid klinik pou Karsinòm selil skuamèz tèt ak kou nan Massachusetts
42 etid pou Karsinòm selil skuamèz tèt ak kou ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site #0131, Boston
- Site#0101, Boston
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06788990A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #7, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07090499Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- Boston Medical Center, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06589804A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Boston
- Research Site, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT05877599A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
- Boston Medical Center, Boston
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 25, 2026 · NCT07219212BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Baystate Medical Center, Springfield
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05136196A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07276399JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- Boston Medical Center, Boston
Ap rekriteFaz 3
Laj 60 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04892173A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06385080Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- Tufts Medical Center, Boston
Ap rekriteFaz 2
Laj 18 a 79 · Tout sèks · Mizajou Sep 22, 2026 · NCT04671667Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07109726Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- Tufts Medical Center, Boston
- Tufts Medical Center Cancer Center Stoneham, Stoneham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT02734537First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06657222ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06597721A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
- Dana Farber Cancer Institute, Boston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06163534A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07182149PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06239220Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Boston Medical Center, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06532279A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital - Dana Farber, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT03526835A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT06150664PDT For Induction Therapy For Head And Neck Cancer
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 14, 2026 · NCT07214987First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT05768139A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- ak 3 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT06993844Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT05726370Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT04777994A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Worcester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 26, 2026 · NCT06256588A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT06064877A Study of DB-1310 in Advanced/Metastatic Solid Tumors
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 6, 2026 · NCT05785741This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 2, 2026 · NCT06451497Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 27, 2026 · NCT07465276Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Jan 26, 2026 · NCT05553782A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 8, 2025 · NCT04370587A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT05941507Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Dana Farber/Partners Cancer Care Inc, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 15, 2025 · NCT04429542Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
- Massachusetts Eye and Ear, Boston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou May 18, 2025 · NCT06744296Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.